Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial ; volume:27 ; number:6 ; day:20 ; month:8 ; year:2024 ; pages:1287-1301 ; date:11.2024
Gastric cancer ; 27, Heft 6 (20.8.2024), 1287-1301, 11.2024

Creator: Boku, Narikazu
Omori, Takeshi
Shitara, Kohei
Sakuramoto, Shinichi
Yamaguchi, Kensei
Kato, Ken
Kadowaki, Shigenori
Tsuji, Kunihiro
Ryu, Min-Hee
Oh, Do-Youn
Oh, Sang Cheul
Rha, Sun Young
Lee, Keun-Wook
Chung, Ik-Joo
Sym, Sun Jin
Chen, Li-Tzong
Chen, Jen-Shi
Bai, Li-Yuan
Nakada, Takashi
Hagihara, Shunsuke
Makino, Reina
Nishiyama, Eiji
Kang, Yoon-Koo

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10120-024-01535-0

URN: urn:nbn:de:101:1-2501162117232.542761591856

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Boku, Narikazu
Omori, Takeshi
Shitara, Kohei
Sakuramoto, Shinichi
Yamaguchi, Kensei
Kato, Ken
Kadowaki, Shigenori
Tsuji, Kunihiro
Ryu, Min-Hee
Oh, Do-Youn
Oh, Sang Cheul
Rha, Sun Young
Lee, Keun-Wook
Chung, Ik-Joo
Sym, Sun Jin
Chen, Li-Tzong
Chen, Jen-Shi
Bai, Li-Yuan
Nakada, Takashi
Hagihara, Shunsuke
Makino, Reina
Nishiyama, Eiji
Kang, Yoon-Koo
SpringerLink (Online service)

Other Objects (12)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer

Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer

Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer

Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer

Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer

Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer

Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial

Related objects

Reset password